Larry Dumont
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Preservation | 48 | 2025 | 346 | 10.350 |
Why?
| | Blood Platelets | 31 | 2024 | 382 | 8.270 |
Why?
| | Platelet Transfusion | 19 | 2023 | 76 | 3.510 |
Why?
| | Erythrocytes | 25 | 2025 | 750 | 3.430 |
Why?
| | Blood Donors | 13 | 2021 | 145 | 2.830 |
Why?
| | Cryopreservation | 11 | 2023 | 115 | 2.810 |
Why?
| | Plateletpheresis | 11 | 2024 | 28 | 2.110 |
Why?
| | Antibodies, Viral | 9 | 2025 | 689 | 1.510 |
Why?
| | Dimethyl Sulfoxide | 3 | 2023 | 42 | 1.170 |
Why?
| | Platelet-Rich Plasma | 2 | 2023 | 44 | 1.080 |
Why?
| | Plasma | 6 | 2014 | 222 | 1.070 |
Why?
| | Pharmaceutical Solutions | 4 | 2014 | 14 | 1.010 |
Why?
| | Antibodies, Neutralizing | 8 | 2025 | 348 | 1.000 |
Why?
| | Leukocyte Reduction Procedures | 8 | 2025 | 29 | 0.960 |
Why?
| | Mannitol | 4 | 2014 | 42 | 0.940 |
Why?
| | Hydrogen-Ion Concentration | 12 | 2024 | 533 | 0.940 |
Why?
| | Membrane Lipids | 3 | 2020 | 81 | 0.920 |
Why?
| | Sodium Chloride | 4 | 2014 | 138 | 0.890 |
Why?
| | Glucose | 8 | 2017 | 1053 | 0.870 |
Why?
| | Blood Component Removal | 5 | 2022 | 26 | 0.850 |
Why?
| | ABO Blood-Group System | 5 | 2020 | 56 | 0.830 |
Why?
| | Adenine | 4 | 2014 | 339 | 0.780 |
Why?
| | Metabolome | 4 | 2020 | 390 | 0.750 |
Why?
| | Erythrocyte Transfusion | 9 | 2021 | 226 | 0.710 |
Why?
| | Glycolysis | 5 | 2021 | 342 | 0.660 |
Why?
| | Metformin | 1 | 2024 | 328 | 0.650 |
Why?
| | Cytoskeleton | 1 | 2022 | 180 | 0.650 |
Why?
| | Humans | 91 | 2025 | 146342 | 0.630 |
Why?
| | Time Factors | 21 | 2023 | 7109 | 0.630 |
Why?
| | Adenosine Triphosphate | 6 | 2015 | 494 | 0.620 |
Why?
| | Solutions | 4 | 2014 | 160 | 0.570 |
Why?
| | Immunization, Passive | 10 | 2025 | 90 | 0.550 |
Why?
| | Hemostasis | 3 | 2021 | 100 | 0.540 |
Why?
| | Glutathione | 2 | 2017 | 369 | 0.530 |
Why?
| | Erythrocyte Membrane | 2 | 2020 | 55 | 0.530 |
Why?
| | Carrier Proteins | 1 | 2022 | 728 | 0.530 |
Why?
| | Blood Transfusion, Autologous | 3 | 2020 | 18 | 0.530 |
Why?
| | Cold Temperature | 3 | 2020 | 208 | 0.510 |
Why?
| | Blood Grouping and Crossmatching | 3 | 2016 | 19 | 0.500 |
Why?
| | Cell Survival | 10 | 2017 | 1105 | 0.460 |
Why?
| | Blood Group Incompatibility | 2 | 2012 | 21 | 0.450 |
Why?
| | Metabolomics | 5 | 2021 | 738 | 0.450 |
Why?
| | Dexamethasone | 1 | 2017 | 368 | 0.440 |
Why?
| | Leukocytes | 3 | 2023 | 301 | 0.440 |
Why?
| | Phosphatidylserines | 2 | 2014 | 62 | 0.430 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 73 | 0.420 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 377 | 0.400 |
Why?
| | Carbon Dioxide | 1 | 2015 | 228 | 0.400 |
Why?
| | Blood Safety | 3 | 2016 | 11 | 0.400 |
Why?
| | Erythrocyte Aggregation | 1 | 2012 | 4 | 0.380 |
Why?
| | Transfusion Reaction | 3 | 2022 | 61 | 0.370 |
Why?
| | Blood Proteins | 1 | 2014 | 239 | 0.370 |
Why?
| | Citrates | 4 | 2017 | 41 | 0.360 |
Why?
| | Oxidative Stress | 5 | 2020 | 1369 | 0.360 |
Why?
| | Dicarboxylic Acids | 1 | 2011 | 12 | 0.350 |
Why?
| | Polyvinyl Chloride | 1 | 2011 | 12 | 0.350 |
Why?
| | Diethylhexyl Phthalate | 1 | 2011 | 13 | 0.350 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2011 | 18 | 0.350 |
Why?
| | Bacteriological Techniques | 2 | 2013 | 66 | 0.350 |
Why?
| | United States Food and Drug Administration | 3 | 2016 | 208 | 0.350 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 116 | 0.330 |
Why?
| | Rejuvenation | 1 | 2011 | 18 | 0.330 |
Why?
| | Minerals | 1 | 2011 | 48 | 0.320 |
Why?
| | Platelet Aggregation | 3 | 2022 | 99 | 0.320 |
Why?
| | Energy Metabolism | 2 | 2021 | 930 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1763 | 0.310 |
Why?
| | Interferon Type I | 2 | 2021 | 147 | 0.310 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 80 | 0.310 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 209 | 0.310 |
Why?
| | Bacteremia | 1 | 2012 | 218 | 0.310 |
Why?
| | Evidence-Based Practice | 1 | 2012 | 231 | 0.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2022 | 704 | 0.300 |
Why?
| | Oxygen | 3 | 2015 | 997 | 0.290 |
Why?
| | Anaerobiosis | 4 | 2015 | 65 | 0.280 |
Why?
| | Testosterone | 3 | 2022 | 419 | 0.280 |
Why?
| | Thrombocytopenia | 2 | 2022 | 206 | 0.280 |
Why?
| | Hemolysis | 7 | 2025 | 242 | 0.280 |
Why?
| | Hemostatics | 2 | 2021 | 66 | 0.270 |
Why?
| | Citric Acid | 3 | 2012 | 33 | 0.260 |
Why?
| | Bacteria | 2 | 2013 | 766 | 0.260 |
Why?
| | Platelet Activation | 2 | 2024 | 99 | 0.250 |
Why?
| | Seroepidemiologic Studies | 3 | 2021 | 171 | 0.240 |
Why?
| | In Vitro Techniques | 4 | 2021 | 1041 | 0.240 |
Why?
| | Leukapheresis | 1 | 2006 | 27 | 0.240 |
Why?
| | Staphylococcal Infections | 1 | 2010 | 397 | 0.230 |
Why?
| | Blood Banks | 4 | 2020 | 50 | 0.230 |
Why?
| | Specimen Handling | 1 | 2007 | 178 | 0.230 |
Why?
| | Photopheresis | 2 | 2018 | 9 | 0.230 |
Why?
| | Lactic Acid | 2 | 2024 | 295 | 0.230 |
Why?
| | Platelet Function Tests | 2 | 2022 | 37 | 0.230 |
Why?
| | Adenosine Diphosphate | 2 | 2022 | 75 | 0.230 |
Why?
| | Blood Transfusion | 4 | 2016 | 394 | 0.220 |
Why?
| | Temperature | 3 | 2014 | 635 | 0.220 |
Why?
| | Blood Coagulation Tests | 2 | 2015 | 72 | 0.220 |
Why?
| | Serologic Tests | 2 | 2022 | 50 | 0.210 |
Why?
| | Oxygen Consumption | 2 | 2024 | 721 | 0.210 |
Why?
| | Platelet Count | 4 | 2020 | 95 | 0.210 |
Why?
| | Anticoagulants | 4 | 2014 | 746 | 0.210 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 585 | 0.200 |
Why?
| | Male | 26 | 2025 | 73396 | 0.200 |
Why?
| | 2,3-Diphosphoglycerate | 2 | 2015 | 32 | 0.200 |
Why?
| | Autoantibodies | 2 | 2021 | 1500 | 0.200 |
Why?
| | Hemoglobins | 4 | 2022 | 384 | 0.190 |
Why?
| | P-Selectin | 3 | 2022 | 29 | 0.180 |
Why?
| | Xenon | 1 | 2022 | 7 | 0.180 |
Why?
| | Neuroacanthocytosis | 1 | 2022 | 5 | 0.180 |
Why?
| | Furocoumarins | 1 | 2022 | 8 | 0.180 |
Why?
| | Refrigeration | 1 | 2022 | 11 | 0.180 |
Why?
| | HMGB1 Protein | 1 | 2022 | 51 | 0.180 |
Why?
| | Adult | 17 | 2025 | 41087 | 0.180 |
Why?
| | Hormone Replacement Therapy | 2 | 2021 | 107 | 0.180 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2022 | 49 | 0.180 |
Why?
| | Flow Cytometry | 1 | 2006 | 1163 | 0.180 |
Why?
| | Hospital Distribution Systems | 1 | 2021 | 1 | 0.180 |
Why?
| | Compassionate Use Trials | 1 | 2021 | 7 | 0.180 |
Why?
| | Female | 21 | 2025 | 79499 | 0.170 |
Why?
| | Radioisotopes | 3 | 2008 | 37 | 0.170 |
Why?
| | Middle Aged | 15 | 2025 | 36619 | 0.170 |
Why?
| | Aged | 13 | 2025 | 26432 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2021 | 218 | 0.160 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 301 | 0.160 |
Why?
| | Nonprescription Drugs | 1 | 2021 | 68 | 0.160 |
Why?
| | Organ Preservation Solutions | 2 | 2012 | 47 | 0.160 |
Why?
| | Adolescent | 8 | 2021 | 22557 | 0.150 |
Why?
| | Taurine | 1 | 2020 | 41 | 0.150 |
Why?
| | Health Services Needs and Demand | 1 | 2021 | 287 | 0.150 |
Why?
| | Prescription Drugs | 1 | 2021 | 110 | 0.150 |
Why?
| | Antibodies, Monoclonal | 2 | 2016 | 1512 | 0.140 |
Why?
| | Cryoprotective Agents | 2 | 2018 | 11 | 0.140 |
Why?
| | Cooperative Behavior | 3 | 2012 | 471 | 0.140 |
Why?
| | Asparagine | 1 | 2018 | 34 | 0.140 |
Why?
| | Freezing | 1 | 2018 | 83 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2023 | 1135 | 0.140 |
Why?
| | Oxidation-Reduction | 3 | 2021 | 1075 | 0.140 |
Why?
| | Cigarette Smoking | 1 | 2020 | 103 | 0.140 |
Why?
| | Aspartic Acid | 1 | 2018 | 88 | 0.140 |
Why?
| | Product Packaging | 2 | 2011 | 6 | 0.140 |
Why?
| | Blood Buffy Coat | 1 | 2018 | 6 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 366 | 0.130 |
Why?
| | Buffers | 2 | 2014 | 56 | 0.130 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 43 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2021 | 8391 | 0.130 |
Why?
| | Nicotine | 1 | 2020 | 337 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 370 | 0.130 |
Why?
| | Chromatography, Liquid | 2 | 2021 | 453 | 0.120 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 55 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2021 | 901 | 0.120 |
Why?
| | Dithiothreitol | 1 | 2016 | 19 | 0.120 |
Why?
| | Histocompatibility Testing | 1 | 2016 | 124 | 0.120 |
Why?
| | Government Regulation | 1 | 2016 | 38 | 0.120 |
Why?
| | Platelet Adhesiveness | 1 | 2015 | 14 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2921 | 0.110 |
Why?
| | Guidelines as Topic | 2 | 2020 | 267 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 576 | 0.110 |
Why?
| | Protein Processing, Post-Translational | 1 | 2018 | 487 | 0.110 |
Why?
| | Transfusion Medicine | 1 | 2015 | 20 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 572 | 0.110 |
Why?
| | Young Adult | 8 | 2021 | 14330 | 0.110 |
Why?
| | False Positive Reactions | 2 | 2016 | 124 | 0.110 |
Why?
| | Cardiac Surgical Procedures | 1 | 2021 | 611 | 0.110 |
Why?
| | Metabolic Networks and Pathways | 1 | 2016 | 175 | 0.110 |
Why?
| | Monocytes | 1 | 2018 | 538 | 0.110 |
Why?
| | Cross-Over Studies | 3 | 2012 | 615 | 0.110 |
Why?
| | Therapeutic Equivalency | 1 | 2014 | 31 | 0.110 |
Why?
| | Gases | 1 | 2014 | 45 | 0.110 |
Why?
| | Hematocrit | 1 | 2014 | 108 | 0.100 |
Why?
| | Osmolar Concentration | 1 | 2014 | 165 | 0.100 |
Why?
| | United States | 8 | 2021 | 16136 | 0.100 |
Why?
| | False Negative Reactions | 2 | 2011 | 61 | 0.100 |
Why?
| | Colony Count, Microbial | 2 | 2011 | 90 | 0.100 |
Why?
| | Blood Coagulation Factors | 1 | 2014 | 71 | 0.100 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2014 | 124 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2015 | 267 | 0.100 |
Why?
| | Disease Progression | 1 | 2021 | 2867 | 0.100 |
Why?
| | Hemorrhage | 1 | 2018 | 825 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2400 | 0.090 |
Why?
| | Vaccination | 1 | 2021 | 1449 | 0.090 |
Why?
| | Hematologic Neoplasms | 2 | 2018 | 170 | 0.090 |
Why?
| | Phosphoric Acids | 1 | 2012 | 14 | 0.090 |
Why?
| | Single-Blind Method | 3 | 2021 | 313 | 0.090 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2012 | 150 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 11821 | 0.090 |
Why?
| | Nitrogen Mustard Compounds | 1 | 2011 | 9 | 0.090 |
Why?
| | Checklist | 1 | 2012 | 105 | 0.080 |
Why?
| | Bacteria, Aerobic | 1 | 2011 | 7 | 0.080 |
Why?
| | Acridines | 1 | 2011 | 10 | 0.080 |
Why?
| | Bacteria, Anaerobic | 1 | 2011 | 25 | 0.080 |
Why?
| | Immunity, Humoral | 2 | 2023 | 121 | 0.080 |
Why?
| | Heparin | 1 | 2012 | 247 | 0.080 |
Why?
| | Klebsiella oxytoca | 1 | 2010 | 1 | 0.080 |
Why?
| | Viridans Streptococci | 1 | 2010 | 7 | 0.080 |
Why?
| | Serratia Infections | 1 | 2010 | 8 | 0.080 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2011 | 28 | 0.080 |
Why?
| | Serratia marcescens | 1 | 2010 | 17 | 0.080 |
Why?
| | Klebsiella Infections | 1 | 2010 | 26 | 0.080 |
Why?
| | Adaptive Immunity | 2 | 2023 | 173 | 0.080 |
Why?
| | Delphi Technique | 1 | 2012 | 350 | 0.080 |
Why?
| | Kinetics | 1 | 2014 | 1553 | 0.080 |
Why?
| | Consensus | 1 | 2012 | 467 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1998 | 0.080 |
Why?
| | Cell Membrane | 1 | 2014 | 701 | 0.080 |
Why?
| | Erythrocyte Count | 2 | 2007 | 20 | 0.080 |
Why?
| | Obesity | 2 | 2020 | 3131 | 0.080 |
Why?
| | Escherichia coli Infections | 1 | 2010 | 125 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 283 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 999 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1298 | 0.070 |
Why?
| | RNA, Viral | 2 | 2025 | 693 | 0.070 |
Why?
| | Drug Combinations | 1 | 2011 | 400 | 0.070 |
Why?
| | Biopsy, Fine-Needle | 1 | 2009 | 79 | 0.070 |
Why?
| | Mice | 5 | 2021 | 18297 | 0.070 |
Why?
| | Publishing | 1 | 2010 | 117 | 0.070 |
Why?
| | Leukocyte Count | 2 | 2007 | 321 | 0.070 |
Why?
| | Thyroid Nodule | 1 | 2009 | 67 | 0.070 |
Why?
| | Genetic Heterogeneity | 1 | 2009 | 67 | 0.070 |
Why?
| | Thrombosis | 1 | 2012 | 398 | 0.070 |
Why?
| | Hospitalization | 3 | 2025 | 2475 | 0.070 |
Why?
| | Lipids | 1 | 2014 | 714 | 0.070 |
Why?
| | Safety Management | 1 | 2009 | 130 | 0.070 |
Why?
| | Streptococcal Infections | 1 | 2010 | 179 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 6034 | 0.060 |
Why?
| | Ultraviolet Rays | 2 | 2022 | 376 | 0.060 |
Why?
| | Transportation | 1 | 2007 | 54 | 0.060 |
Why?
| | Proteome | 1 | 2012 | 520 | 0.060 |
Why?
| | Animals | 6 | 2022 | 38106 | 0.060 |
Why?
| | Cell Separation | 1 | 2007 | 300 | 0.060 |
Why?
| | Escherichia coli | 1 | 2010 | 832 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2010 | 459 | 0.060 |
Why?
| | Research Design | 1 | 2012 | 1143 | 0.060 |
Why?
| | Survival Analysis | 1 | 2009 | 1378 | 0.060 |
Why?
| | Risk Assessment | 2 | 2012 | 3712 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1591 | 0.050 |
Why?
| | Genotype | 1 | 2009 | 1879 | 0.050 |
Why?
| | Pregnancy | 1 | 2017 | 7230 | 0.050 |
Why?
| | Prevalence | 2 | 2021 | 2861 | 0.050 |
Why?
| | Quality Control | 2 | 2016 | 163 | 0.050 |
Why?
| | Neutralization Tests | 1 | 2023 | 74 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 2003 | 80 | 0.050 |
Why?
| | CD40 Ligand | 1 | 2022 | 32 | 0.050 |
Why?
| | Blood Cell Count | 1 | 2002 | 56 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1064 | 0.050 |
Why?
| | Glycerol | 1 | 2022 | 90 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2023 | 129 | 0.040 |
Why?
| | Prospective Studies | 3 | 2022 | 8123 | 0.040 |
Why?
| | Masculinity | 1 | 2021 | 10 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2020 | 17438 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2022 | 188 | 0.040 |
Why?
| | Convalescence | 1 | 2021 | 19 | 0.040 |
Why?
| | Ranitidine | 1 | 2021 | 14 | 0.040 |
Why?
| | Thrombin | 1 | 2022 | 175 | 0.040 |
Why?
| | Medically Underserved Area | 1 | 2021 | 102 | 0.040 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2021 | 51 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.040 |
Why?
| | Hematologic Tests | 1 | 2020 | 22 | 0.040 |
Why?
| | Osmotic Pressure | 1 | 2020 | 41 | 0.040 |
Why?
| | Ferritins | 1 | 2020 | 69 | 0.040 |
Why?
| | Coronavirus | 1 | 2021 | 47 | 0.040 |
Why?
| | Treatment Failure | 1 | 2021 | 361 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 432 | 0.040 |
Why?
| | Signal Transduction | 1 | 2014 | 5246 | 0.040 |
Why?
| | Polycythemia | 1 | 2020 | 25 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2070 | 0.040 |
Why?
| | Software | 1 | 2005 | 676 | 0.040 |
Why?
| | Graft Survival | 1 | 2002 | 523 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 440 | 0.040 |
Why?
| | Hypogonadism | 1 | 2020 | 89 | 0.040 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 1 | 2018 | 2 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2021 | 179 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 598 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 517 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2020 | 541 | 0.030 |
Why?
| | Methoxsalen | 1 | 2018 | 4 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 2018 | 29 | 0.030 |
Why?
| | Annexin A5 | 1 | 2018 | 23 | 0.030 |
Why?
| | Developing Countries | 1 | 2020 | 312 | 0.030 |
Why?
| | Patient Safety | 1 | 2021 | 352 | 0.030 |
Why?
| | Methylation | 1 | 2018 | 241 | 0.030 |
Why?
| | Child | 3 | 2022 | 22693 | 0.030 |
Why?
| | Tissue Donors | 1 | 2021 | 425 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 540 | 0.030 |
Why?
| | Thrombelastography | 1 | 2018 | 182 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 2081 | 0.030 |
Why?
| | Child, Preschool | 2 | 2022 | 11913 | 0.030 |
Why?
| | Methods | 1 | 2016 | 68 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2016 | 43 | 0.030 |
Why?
| | Cross Reactions | 1 | 2016 | 130 | 0.030 |
Why?
| | Blotting, Western | 1 | 2018 | 1177 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2126 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 779 | 0.030 |
Why?
| | Hemorheology | 1 | 2015 | 24 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 883 | 0.030 |
Why?
| | Erythrocyte Deformability | 1 | 2015 | 23 | 0.030 |
Why?
| | Biochemistry | 1 | 2015 | 36 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2016 | 134 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1327 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 384 | 0.030 |
Why?
| | Chromium Radioisotopes | 1 | 2014 | 4 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 594 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 543 | 0.030 |
Why?
| | Perfusion | 1 | 2015 | 255 | 0.030 |
Why?
| | Antibodies | 1 | 2016 | 400 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2016 | 379 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2016 | 247 | 0.030 |
Why?
| | Models, Theoretical | 2 | 2009 | 561 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2021 | 3125 | 0.020 |
Why?
| | Models, Biological | 1 | 2021 | 1761 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1707 | 0.020 |
Why?
| | Veterans | 1 | 2025 | 1650 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 544 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3647 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 109 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2458 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1203 | 0.020 |
Why?
| | Hospitals | 1 | 2016 | 738 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2502 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2018 | 4118 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4340 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1036 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2439 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2363 | 0.020 |
Why?
| | Diphosphoglyceric Acids | 1 | 2008 | 3 | 0.020 |
Why?
| | Alkalies | 1 | 2008 | 5 | 0.020 |
Why?
| | Aerobiosis | 1 | 2008 | 18 | 0.020 |
Why?
| | Automation | 1 | 2007 | 104 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10921 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 1077 | 0.020 |
Why?
| | Equipment Design | 1 | 2007 | 520 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 161 | 0.010 |
Why?
| | Acute Lung Injury | 1 | 2009 | 312 | 0.010 |
Why?
| | Computer Simulation | 1 | 2009 | 1014 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1888 | 0.010 |
Why?
| | Sepsis | 1 | 2009 | 669 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 6077 | 0.010 |
Why?
|
|
Dumont's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|